Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:crizotinib
go back to main search page
Accession:CHEBI:64310 term browser browse the term
Definition:A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Synonyms:exact_synonym: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine
 related_synonym: (R)-crizotinib;   Formula=C21H22Cl2FN5O;   InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1;   InChIKey=KTEIFNKAUNYNJU-GFCCVEGCSA-N;   PF 2341066;   SMILES=C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl;   crizotinibum
 alt_id: CHEBI:77554
 xref: CAS:877399-52-5;   Drug_Central:4187;   KEGG:D09731;   LINCS:LSM-1027
 xref_mesh: MESH:C551994
 xref: PMID:21308771;   PMID:22129595;   PMID:22129984;   PMID:22191798;   PMID:22215748;   PMID:22233293;   PMID:22235099;   PMID:22277784;   PMID:22282074;   PMID:22311682;   PMID:22316363;   PMID:22321987;   PMID:22323827;   PMID:22385925;   PMID:22397764;   PMID:22435662;   PMID:22443113;   PMID:24427836;   PMID:24444403;   PMID:24455567;   PMID:24486291;   PMID:24491302;   PMID:24556908;   Reaxys:12133926;   Wikipedia:Crizotinib
 cyclic_relationship: is_enantiomer_of CHEBI:77555


show annotations for term's descendants           Sort by:
 
crizotinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 multiple interactions
decreases activity
EXP crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]
crizotinib results in decreased activity of ABCB1 protein
CTD PMID:22233293 PMID:28369651 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
Ensembl chr 7:87,503,017...87,713,323
JBrowse link
G ABCG2 ATP binding cassette subfamily G member 2 (Junior blood group) decreases activity EXP crizotinib results in decreased activity of ABCG2 protein CTD PMID:28369651 NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
JBrowse link
G ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase decreases activity ISO crizotinib results in decreased activity of ABL1 protein CTD PMID:21812414 NCBI chr 9:130,713,881...130,887,675
Ensembl chr 9:130,713,016...130,887,675
JBrowse link
G ACACA acetyl-CoA carboxylase alpha increases phosphorylation EXP crizotinib results in increased phosphorylation of ACACA protein CTD PMID:23707608 NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836
JBrowse link
G AKT1 AKT serine/threonine kinase 1 decreases phosphorylation
multiple interactions
EXP crizotinib results in decreased phosphorylation of AKT1 protein
EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]
CTD PMID:22553343 PMID:22729845 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
JBrowse link
G ALK ALK receptor tyrosine kinase decreases response to substance
affects response to substance
multiple interactions
decreases activity
decreases phosphorylation
decreases stability
increases mutagenesis
EXP
ISO
ALK gene mutant form results in decreased susceptibility to crizotinib; ALK gene SNP results in decreased susceptibility to crizotinib; ALK protein mutant form results in decreased susceptibility to crizotinib
ALK protein affects the susceptibility to crizotinib
[ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to Crizotinib; [Crizotinib results in increased mutagenesis of ALK gene mutant form] which results in decreased susceptibility to Crizotinib; [Crizotinib results in increased mutagenesis of ALK protein mutant form] which results in decreased susceptibility to Crizotinib; [Crizotinib results in increased mutagenesis of ALK protein mutant form] which results in increased activity of ALK protein; [Ethylnitrosourea results in increased mutagenesis of ALK protein] inhibits the reaction [Crizotinib results in decreased phosphorylation of ALK protein]; [Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to Crizotinib; ALK gene SNP inhibits the reaction [Crizotinib results in decreased phosphorylation of ALK protein mutant form]; ALK protein mutant form inhibits the reaction [Crizotinib binds to and results in decreased activity of ALK protein]; ALK protein mutant form inhibits the reaction [Crizotinib results in decreased activity of ALK protein]; ALK protein mutant form inhibits the reaction [Crizotinib results in decreased phosphorylation of ALK protein]; Crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]; Crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]; Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]; Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein]; Crizotinib results in decreased phosphorylation of and results in decreased activity of ALK protein mutant form
Crizotinib results in decreased activity of ALK protein; Crizotinib results in decreased activity of ALK protein mutant form
crizotinib results in decreased phosphorylation of ALK protein; crizotinib results in decreased phosphorylation of ALK protein mutant form
crizotinib results in decreased stability of ALK protein mutant form
crizotinib results in increased mutagenesis of ALK gene mutant form; crizotinib results in increased mutagenesis of ALK protein mutant form
crizotinib results in decreased activity of ALK protein mutant form
CTD PMID:20979473 PMID:21030459 PMID:21502504 PMID:21767331 PMID:21791641 PMID:21812414 PMID:21838707 PMID:21948233 PMID:22034911 PMID:22072639 PMID:22129595 PMID:22235099 PMID:22277784 PMID:22286764 PMID:22553343 PMID:22659414 PMID:22789543 PMID:22912387 PMID:23104988 PMID:29458018 NCBI chr 2:29,190,992...29,921,589
Ensembl chr 2:29,192,774...29,921,586
JBrowse link
G BCL2L11 BCL2 like 11 increases expression
multiple interactions
affects response to substance
EXP crizotinib results in increased expression of BCL2L11 protein
BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased expression of BCL2L11 protein]
BCL2L11 protein affects the susceptibility to crizotinib
CTD PMID:22729845 NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,445
JBrowse link
G BIRC2 baculoviral IAP repeat containing 2 decreases expression
multiple interactions
EXP crizotinib results in decreased expression of BIRC2 protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC2 protein]
CTD PMID:22729845 NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670
JBrowse link
G BIRC5 baculoviral IAP repeat containing 5 decreases expression
multiple interactions
EXP crizotinib results in decreased expression of BIRC5 protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC5 protein]
CTD PMID:22729845 NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
JBrowse link
G CACNA1C calcium voltage-gated channel subunit alpha1 C decreases activity EXP crizotinib results in decreased activity of CACNA1C protein CTD PMID:23707608 NCBI chr12:1,969,552...2,697,950
Ensembl chr12:1,970,786...2,697,950
JBrowse link
G CASP3 caspase 3 multiple interactions
increases cleavage
increases activity
EXP
ISO
BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased cleavage of CASP3 protein]
[crizotinib co-treated with 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one] results in increased cleavage of CASP3 protein
crizotinib results in increased activity of CASP3 protein
CTD PMID:22729845 PMID:22789543 PMID:23707608 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CASP7 caspase 7 increases activity EXP crizotinib results in increased activity of CASP7 protein CTD PMID:23707608 NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
JBrowse link
G CASP8 caspase 8 increases cleavage EXP Crizotinib results in increased cleavage of CASP8 protein CTD PMID:31706006 NCBI chr 2:201,233,443...201,287,711
Ensembl chr 2:201,233,443...201,287,711
JBrowse link
G CD44 CD44 molecule (Indian blood group) decreases expression EXP crizotinib results in decreased expression of CD44 mRNA; crizotinib results in decreased expression of CD44 protein CTD PMID:22973962 NCBI chr11:35,139,168...35,232,402
Ensembl chr11:35,138,882...35,232,402
Ensembl chr11:35,138,882...35,232,402
JBrowse link
G CDA cytidine deaminase decreases expression
multiple interactions
EXP crizotinib results in decreased expression of CDA protein
[crizotinib results in decreased expression of CDA protein] which results in increased susceptibility to gemcitabine
CTD PMID:22973962 NCBI chr 1:20,589,097...20,618,903
Ensembl chr 1:20,589,086...20,618,903
JBrowse link
G CRKL CRK like proto-oncogene, adaptor protein multiple interactions EXP [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein CTD PMID:22683780 NCBI chr22:20,917,407...20,953,747
Ensembl chr22:20,917,407...20,953,747
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 increases expression EXP crizotinib results in increased expression of CYP3A4 mRNA CTD PMID:23129213 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G EGF epidermal growth factor multiple interactions
decreases response to substance
EXP EGF protein inhibits the reaction [Crizotinib results in decreased phosphorylation of AKT1 protein]; EGF protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK1 protein]; EGF protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to Crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to Crizotinib]
EGF protein results in decreased susceptibility to crizotinib
CTD PMID:22553343 NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
JBrowse link
G EGFR epidermal growth factor receptor decreases response to substance
multiple interactions
EXP EGFR protein mutant form results in decreased susceptibility to crizotinib; EGFR protein results in decreased susceptibility to crizotinib
[EGFR protein results in increased phosphorylation of EGFR protein] which results in decreased susceptibility to crizotinib; EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to crizotinib]; EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]
CTD PMID:21791641 PMID:22235099 PMID:22277784 PMID:22553343 NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
JBrowse link
G EML4 EMAP like 4 decreases stability
multiple interactions
increases mutagenesis
EXP crizotinib results in decreased stability of EML4 protein mutant form
[crizotinib results in increased mutagenesis of EML4 gene mutant form] which results in decreased susceptibility to crizotinib
CTD PMID:21502504 PMID:22912387 NCBI chr 2:42,169,353...42,332,548
Ensembl chr 2:42,169,353...42,332,548
JBrowse link
G EPCAM epithelial cell adhesion molecule decreases expression EXP Crizotinib results in decreased expression of EPCAM mRNA; Crizotinib results in decreased expression of EPCAM protein CTD PMID:22973962 NCBI chr 2:47,369,311...47,387,020
Ensembl chr 2:47,345,158...47,387,601
JBrowse link
G F3 coagulation factor III, tissue factor increases expression EXP crizotinib results in increased expression of F3 protein CTD PMID:25569083 NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
JBrowse link
G FADS2 fatty acid desaturase 2 increases expression EXP crizotinib results in increased expression of FADS2 mRNA CTD PMID:23707608 NCBI chr11:61,816,203...61,867,354
Ensembl chr11:61,792,980...61,867,354
JBrowse link
G FASN fatty acid synthase increases expression EXP crizotinib results in increased expression of FASN mRNA CTD PMID:23707608 NCBI chr17:82,078,338...82,098,303
Ensembl chr17:82,078,338...82,098,294
JBrowse link
G FGFR1 fibroblast growth factor receptor 1 multiple interactions EXP [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 8:38,411,143...38,468,635
Ensembl chr 8:38,400,215...38,468,834
JBrowse link
G FSHB follicle stimulating hormone subunit beta decreases secretion EXP crizotinib results in decreased secretion of FSHB protein CTD PMID:22488744 NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,016...30,235,261
Ensembl chr11:30,231,016...30,235,261
JBrowse link
G GPT glutamic--pyruvic transaminase increases secretion EXP Crizotinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
JBrowse link
G HBEGF heparin binding EGF like growth factor multiple interactions
decreases response to substance
EXP EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein] CTD PMID:22553343 NCBI chr 5:140,332,843...140,346,603
Ensembl chr 5:140,332,843...140,346,603
JBrowse link
G HGF hepatocyte growth factor multiple interactions EXP [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; [crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein; [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 7:81,699,006...81,770,438
Ensembl chr 7:81,699,010...81,770,438
JBrowse link
G HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase increases expression EXP crizotinib results in increased expression of HMGCR mRNA CTD PMID:23707608 NCBI chr 5:75,336,334...75,362,116
Ensembl chr 5:75,336,329...75,362,101
JBrowse link
G HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 increases expression EXP crizotinib results in increased expression of HMGCS1 mRNA CTD PMID:23707608 NCBI chr 5:43,287,470...43,313,477
Ensembl chr 5:43,287,470...43,313,512
JBrowse link
G INSIG1 insulin induced gene 1 increases expression EXP crizotinib results in increased expression of INSIG1 mRNA CTD PMID:23707608 NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235
JBrowse link
G KCNH2 potassium voltage-gated channel subfamily H member 2 decreases activity EXP crizotinib results in decreased activity of KCNH2 protein CTD PMID:23707608 NCBI chr 7:150,944,956...150,978,321
Ensembl chr 7:150,944,961...150,978,321
JBrowse link
G KIT KIT proto-oncogene, receptor tyrosine kinase decreases response to substance EXP KIT gene mutant form results in decreased susceptibility to crizotinib CTD PMID:22277784 NCBI chr 4:54,657,957...54,740,715
Ensembl chr 4:54,657,918...54,740,715
JBrowse link
G KRAS KRAS proto-oncogene, GTPase decreases response to substance EXP KRAS protein mutant form results in decreased susceptibility to crizotinib CTD PMID:22235099 NCBI chr12:25,205,246...25,250,929
Ensembl chr12:25,205,246...25,250,936
JBrowse link
G LCK LCK proto-oncogene, Src family tyrosine kinase decreases activity EXP crizotinib results in decreased activity of LCK protein CTD PMID:21812414 NCBI chr 1:32,251,265...32,286,165
Ensembl chr 1:32,251,239...32,286,165
JBrowse link
G LHB luteinizing hormone subunit beta decreases secretion EXP crizotinib results in decreased secretion of LHB protein CTD PMID:22488744 NCBI chr19:49,015,980...49,017,091
Ensembl chr19:49,015,980...49,017,090
Ensembl chr19:49,015,980...49,017,090
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions
decreases phosphorylation
EXP [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein] CTD PMID:21266357 PMID:21502504 PMID:22034911 PMID:22553343 PMID:22683780 PMID:22729845 PMID:23104988 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680
Ensembl chr22:21,754,500...21,867,680
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions
decreases phosphorylation
EXP [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein] CTD PMID:21266357 PMID:21502504 PMID:22034911 PMID:22553343 PMID:22683780 PMID:22729845 PMID:23104988 NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
JBrowse link
G MET MET proto-oncogene, receptor tyrosine kinase decreases activity
affects response to substance
increases response to substance
increases mutagenesis
multiple interactions
decreases phosphorylation
EXP crizotinib results in decreased activity of MET protein
MET protein affects the susceptibility to Crizotinib
MET gene mutant form results in increased susceptibility to crizotinib
crizotinib results in increased mutagenesis of MET protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to Crizotinib; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; [Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [Crizotinib results in increased mutagenesis of MET protein] inhibits the reaction [Crizotinib binds to and results in decreased activity of MET protein]; [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Crizotinib binds to and results in decreased activity of MET protein; Crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of AKT1 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK1 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MET protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of STAT3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BCL2L11 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BIRC2 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BIRC5 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of XIAP protein]
CTD PMID:21266357 PMID:21405128 PMID:21812414 PMID:22233293 PMID:22683780 PMID:22729845 PMID:22948846 PMID:31639374 PMID:31706006 NCBI chr 7:116,672,196...116,798,386
Ensembl chr 7:116,672,196...116,798,386
Ensembl chr 7:116,672,196...116,798,386
JBrowse link
G MST1R macrophage stimulating 1 receptor decreases activity ISO crizotinib results in decreased activity of MST1R protein CTD PMID:21812414 NCBI chr 3:49,886,471...49,903,873
Ensembl chr 3:49,887,002...49,903,873
JBrowse link
G MYCN MYCN proto-oncogene, bHLH transcription factor multiple interactions EXP Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]; Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein] CTD PMID:22286764 NCBI chr 2:15,940,550...15,947,004
Ensembl chr 2:15,940,550...15,947,007
JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 increases cleavage
multiple interactions
EXP Crizotinib results in increased cleavage of PARP1 protein
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Crizotinib results in increased cleavage of PARP1 protein]
CTD PMID:31639374 PMID:31706006 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
JBrowse link
G PROM1 prominin 1 decreases expression EXP Crizotinib results in decreased expression of PROM1 mRNA; Crizotinib results in decreased expression of PROM1 protein CTD PMID:22973962 NCBI chr 4:15,968,226...16,084,059
Ensembl chr 4:15,963,076...16,084,378
JBrowse link
G ROS1 ROS proto-oncogene 1, receptor tyrosine kinase decreases phosphorylation EXP crizotinib results in decreased phosphorylation of ROS protein mutant form CTD PMID:22617245 NCBI chr 6:117,287,353...117,426,065
Ensembl chr 6:117,288,300...117,425,855
Ensembl chr 6:117,288,300...117,425,855
JBrowse link
G RPS6 ribosomal protein S6 decreases phosphorylation EXP crizotinib results in decreased phosphorylation of RPS6 protein CTD PMID:22034911 NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236
JBrowse link
G SCN5A sodium voltage-gated channel alpha subunit 5 decreases activity EXP crizotinib results in decreased activity of SCN5A protein CTD PMID:23707608 NCBI chr 3:38,548,061...38,649,687
Ensembl chr 3:38,548,057...38,649,687
Ensembl chr 3:38,548,057...38,649,687
JBrowse link
G SREBF2 sterol regulatory element binding transcription factor 2 increases expression EXP crizotinib results in increased expression of SREBF2 mRNA CTD PMID:23707608 NCBI chr22:41,833,105...41,907,308
Ensembl chr22:41,833,079...41,907,307
JBrowse link
G STAT3 signal transducer and activator of transcription 3 decreases phosphorylation
multiple interactions
EXP crizotinib results in decreased phosphorylation of STAT3 protein
[[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of STAT3 protein]
CTD PMID:22034911 PMID:22553343 PMID:22683780 PMID:22729845 NCBI chr17:42,313,324...42,388,502
Ensembl chr17:42,313,324...42,388,482
Ensembl chr17:42,313,324...42,388,482
Ensembl chr17:42,313,324...42,388,482
JBrowse link
G TEK TEK receptor tyrosine kinase decreases activity ISO crizotinib results in decreased activity of TEK protein CTD PMID:21812414 NCBI chr 9:27,109,141...27,230,178
Ensembl chr 9:27,109,141...27,230,174
JBrowse link
G TGFA transforming growth factor alpha multiple interactions
decreases response to substance
EXP EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to crizotinib]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein] CTD PMID:22553343 NCBI chr 2:70,447,284...70,553,826
Ensembl chr 2:70,447,284...70,554,193
JBrowse link
G TWIST1 twist family bHLH transcription factor 1 decreases response to substance EXP TWIST1 protein results in decreased susceptibility to crizotinib CTD PMID:22155737 NCBI chr 7:19,113,047...19,117,636
Ensembl chr 7:19,020,991...19,117,636
JBrowse link
G VIM vimentin decreases expression EXP crizotinib results in decreased expression of VIM protein CTD PMID:22973962 NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
JBrowse link
G XIAP X-linked inhibitor of apoptosis decreases expression
multiple interactions
EXP crizotinib results in decreased expression of XIAP protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of XIAP protein]
CTD PMID:22729845 NCBI chr  X:123,859,708...123,913,972
Ensembl chr  X:123,859,724...123,913,976
Ensembl chr  X:123,859,724...123,913,976
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 24381
    role 24291
      application 23783
        indicator 9353
          biomarker 7083
            crizotinib 54
              rac-crizotinib 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 24381
    subatomic particle 24338
      composite particle 24338
        hadron 24338
          baryon 24338
            nucleon 24338
              atomic nucleus 24338
                atom 24338
                  main group element atom 24185
                    p-block element atom 24185
                      carbon group element atom 23965
                        carbon atom 23925
                          organic molecular entity 23925
                            organic molecule 23807
                              organic cyclic compound 23092
                                organic heterocyclic compound 21232
                                  heteroarene 18130
                                    monocyclic heteroarene 14679
                                      azole 13959
                                        diazole 9024
                                          pyrazoles 1843
                                            pyrazolylpiperidine 54
                                              3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine 54
                                                crizotinib 54
                                                  rac-crizotinib 0
paths to the root